Podcasts about discontinuation

Welcome to the latest Midlife Minute. Today, we're discussing how oral contraceptives and Depo Provera can impact women's bone health over time.Stay tuned as I walk you through the research, prescribing trends, and ways women can support their bone health. IN THIS EPISODE, YOU WILL LEARN: How peak bone mass in adolescence affects bone health later in life How oral contraceptives can interfere with the bone development of young women The lack of informed conversations about the bone health risks associated with long-term contraceptive use Why Depo Provera may have a stronger impact on bone density than oral contraceptives The importance of nutrition and strength training for supporting bone health How hormonal contraceptives can affect the gut microbiome and immune system What you need to consider regarding your bone density and long-term health if you've been using oral contraceptives or Depo for many years Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Resources: Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls doi:10.1016/j.jadohealth.2004.07.005 Oral Contraceptive Use and Bone Density Change in Adolescent and Young Adult Women: A Prospective Study of Age, Hormone Dose, and Discontinuation doi:10.1210/jc.2010-3027 Adolescent use of combined hormonal contraception and peak bone mineral density accrual: A meta-analysis of international prospective controlled studies doi:10.1111/cen.13932 No need to specialize: reproductive health is for all adolescents doi:10.1016/j.jpag.2006.01.055 Injectable Hormone Contraception and Bone Density: Results from a Prospective Study doi:10.1097/00001648-200209000-00015 Hormonal contraception and the development of autoimmunity: A review of the literature doi:10.1080/00243639.2017.1360065 Oral contraceptives, reproductive factors and risk of inflammatory bowel disease doi:10.1136/gutjnl-2012-302362 Combined oral contraceptive use and the risk of systemic lupus erythematosus doi:10.1002/art.24398 Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility doi:10.1371/journal.pone.0149094 The Experience of Surviving a High-Risk Pregnancy doi:10.1080/23293691.2016.1166104 Effects of 0.9 mg Recombinant Human Thyrotropin on Thyroid Size and Function in Normal Subjects: A Randomized, Double-Blind, Cross-Over Trial doi:10.1210/jc.2004-0914  

Un nouvel épisode du Pharmascope est disponible! Dans ce 178e épisode, Nicolas, Olivier et Amélie tentent de pondre des réponses un tant soi peu intelligentes à vos excellentes questions. Nous discutons d'ajustement de lévothyroxine, du suivi des IECA/ARA, du rôle de la cariprazine et de l'impact des inhibiteurs du SGLT-2 sur le magnésium.   Les objectifs pour cet épisode sont les suivants: Discuter des modalités d'ajustement de la lévothyroxine et de la déprescription potentielle de celle-ci Discuter des suivis de laboratoire suivant l'initiation d'un ARA ou d'un IECA Discuter des évidences portant sur l'utilisation de la cariprazine Discuter de l'impact des  inhibiteurs du SGLT-2 sur le magnésium Ressources pertinentes en lien avec l'épisode Jonklaas J, et coll; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. Van Uytfanghe K, et coll. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status. Thyroid. 2023 Sep;33(9):1013-1028. Ravensberg J, et coll. Discontinuation of Levothyroxine in Adults Aged 60 Years or Older. JAMA. 2026 Apr 6;335(17):1491–8. RPE de néphrologie de l'APES. Place des IECA et des ARA dans le traitement de la maladie rénale chronique. Septembre 2025. Bhandari S, et coll; STOP ACEi Trial Investigators. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022 Dec 1;387(22):2021-2032. Clase CM, et coll. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017;91:683-90. Garlo KG, et coll. Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease. JAMA Netw Open 2018;1:e183874. Monographie de produit, Abbvie. VRAYLAR (cariprazine). Canada, 6 mars 2024. Barabassy A, et coll. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995. Németh G, et coll. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 Mar 18;389(10074):1103-1113. Fava M, et coll. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018 Nov;33(6):312-321. Durgam S, et coll. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016 Mar;77(3):371-8. Barabassy A, Csehi R, Dombi ZB, Szatmári B, Brevig T, Németh G. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995. Zhang J, et coll. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Kidney360. 2022 Jan 19;3(3):477-487. Toto RD, et coll. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. J Diabetes Complications. 2019 Oct;33(10):107402.

Welcome to the first episode in this week's triple-header of late-breaking clinical trial coverage from Heart Rhythm 2026 in Chicago. In this episode Melissa E. Middeldorp, MPH, PhD from the Digital Education Committee sits down with David H. Birnie, MD and T. Jared Bunch, MD, FHRS to talk through this exciting late breaker. This late-breaking substudy of the ALONE-AF trial presented at Heart Rhythm 2026 evaluated whether discontinuing oral anticoagulation (OAC) after successful atrial fibrillation ablation impacts cognitive function in patients without long-term recurrence. The findings suggest that stopping OAC approximately one year post-ablation does not adversely affect cognitive outcomes, with cognitive scores improving similarly in both discontinuation and continuation groups among patients who remained arrhythmia-free. These results support the potential safety of OAC discontinuation in selected patients, while addressing an important gap in post-ablation management. Learning Objectives Understand the clinical rationale and current uncertainty surrounding continuation versus discontinuation of oral anticoagulation after successful AF ablation. Evaluate the impact of anticoagulation discontinuation on cognitive function in patients without recurrent atrial fibrillation. Apply emerging evidence from ALONE-AF and related studies to inform individualized decision-making on long-term anticoagulation management post-ablation.   Podcast Contributors Melissa E. Middeldorp, MPH, PhD David H. Birnie, MD T. Jared Bunch, MD, FHRS   Contributor Information: M. Middeldorp Nothing to disclose. D. Birnie Nothing to disclose.  T.J. Bunch • Honoraria/Speaking/Teaching/Consulting: Heart Rhythm Society, Pfizer  

-Season ticket holder, Phil calls in, who has been to every home game since Haymarket Park opened in 2002Our Sponsors:* Check out Hims: https://hims.com/EARLYBREAKAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Over 30 million Americans have been told a 19 billion dollar lie. Find out what doctors don't tell you about SSRI side effects, antidepressant effectiveness, and antidepressant risks that affect more people than you think. 0:00 Introduction: The 19 billion dollar lie1:12 Irving Kirsch and medical research bias2:09 Hamilton Depression Scale 2:59 Placebo vs. drug study for antidepressant effectiveness4:16 Antidepressant side effects4:33 Post-SSRI sexual dysfunction and emotional blunting5:49 Antidepressants and the placebo effect explained7:38 Natural antidepressants Download Dr. Berg's Free Daily Health Routine: https://drbrg.co/45qtO07Antidepressant effectiveness may be overstated. Irving Kirsch examined clinical trials on antidepressants and found that around 78% of them were unpublished, rewritten, or contained inflated results.The “gold standard” for measuring depression is the Hamilton Depression Rating Scale (HAM-D), which relies on subjective reporting and was not originally created to diagnose depression.In placebo-controlled trials, antidepressants did not significantly improve depression more than a sugar pill. A good night's sleep can improve the symptoms of depression significantly more than medication. Antidepressants come with a black box warning and many other side effects, including the following:• Sexual dysfunction • Post-SSRI sexual dysfunction • Emotional blunting• Discontinuation syndrome• Insomnia• Nausea• Anxiety• DepressionExercise, St. John's wort, omega-3s, and adequate sleep can help improve the symptoms of depression naturally. Dr. Eric Berg DC Bio:Dr. Berg, age 61, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

Discontinuation of Levothyroxine in Adults Aged 60 Years or Older - Link(259) Os “valores normais” da tiroide deveriam mudar? - Link---Android & iOS app MGFamiliar - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Link⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---Subscreva o Podcast MGFamiliar para não perder qualquer um dos nossos episódios. Além disso, considere deixar-nos uma revisão ou um comentário no Apple Podcasts ou no Spotify.---MusicFiesta de la Vida by Aaron Kenny - ⁠Link—Este podcast destina-se a médicos e os conteúdos nele partilhados não devem ser usados para decisões individuais sem aconselhamento médico. Para tal, fale com o seu médico.

Philippe Pinel remarked in 1800 that "It is an art of no little importance to administer medicines properly, but it is an art of much greater and more difficult acquisition to know when to suspend or altogether to omit them." This insight remains profoundly relevant today, especially in hospice care, where inappropriate prescribing is a common issue. Studies show that 20%–70% of hospice patients receive at least one unnecessary medication near the end of life, including drugs like antihypertensives, statins, and vitamins. In this episode of the GeriPal Podcast, we tackle the pressing topic of deprescribing at the end of life with expert guests Jennifer Tjia, Jon Furuno, and Simon Mooijaart. The conversation focuses on identifying medications that should almost always be discontinued—such as statins, osteoporosis meds, finasteride, and vitamins, which offer minimal benefit for patients with limited life expectancy. We also delve into more nuanced cases, such as antithrombotics, which present complex decisions that challenge clinicians, particularly when prognosis spans the many weeks to months range. Finally, we explore practical strategies for engaging patients and families in deprescribing conversations. Our guests highlight tools such as the FRAME mnemonic (Focus on the goals of care, Review current medications, Assess each medication's risk/benefit, Minimize the medication burden, and Evaluate regularly) and the Goal Concurrent Prescribing tool, which helps ensure medication decisions align with patients' values and end-of-life priorities. By: Eric Widera Other resources discussed in the podcast Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission," JAGS. 2025 Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. 2025 Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial. 2024 Perspectives on deprescribing in palliative care. Expert Review of Clinical Pharmacology. 2023 Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Results of a European Delphi study. Thrombosis Research. 2025 Human-Centered Design Development and Acceptability Testing of a Goal Concordant Prescribing Program in Hospice. JPM 2025 Reduction of Antihypertensive Treatment in Nursing Home Residents. NEJM 2025  

Few medications in addiction treatment generate as much debate as buprenorphine.After receiving significant listener feedback describing difficult experiences with this medication—particularly around discontinuation—Terri sits down with returning guest Dr. Stuart Gitlow for a candid, science-based discussion about one of the most widely used treatments for opioid use disorder.In this episode, we explore:• The science behind medication for opioid use disorder (MOUD)• Why buprenorphine has helped many patients• Reported challenges with tapering and discontinuation• Post-acute withdrawal symptoms (PAWS)• The importance of informed consent and realistic expectationsThis conversation does not dismiss patient experiences, nor does it ignore the life-saving role buprenorphine has played in recovery. Instead, it brings nuance to a complex issue—balancing clinical evidence with lived experience.Whether you are a provider, patient, policymaker, or simply interested in addiction medicine, this episode offers thoughtful insight into efficacy, expectations, and long-term outcomes.More from Rxpert Solutions: https://www.rxpert.solutions/?utm_source=spotify&utm_medium=insights&utm_campaign=buprenorphine

welcome to wall-e's tech briefing for monday, february 16th! dive into today's top tech stories: meta's smart glasses with facial recognition: plans to introduce "name tag," a feature to identify individuals using ai, initially delayed due to privacy concerns but now positioning to launch due to favorable political climate. ai advancements at airbnb: company's ai agent now handles a third of support inquiries in north america, potentially surpassing human assistance quality under new cto ahmad al-dahle. openai's controversial model retirement: discontinuation of gpt-4o due to numerous lawsuits, despite affecting a significant user base, alongside other chatgpt model retirements. figure technologies data breach: social engineering attack by shinyhunters leaks 2.5gb of customer data with responses including free credit monitoring for affected users. roku's strategic streaming bundles: plans for 2026 aim to offer cost-effective options for viewers, including "howdy," an ad-free service with partners like hbo max, following a strong financial quarter. stay tuned for tomorrow's tech updates!

Today, I'm joined by Geoff Cook, CEO of Noom.   Evolved from behavior change app to clinical health platform, Noom combines personalized coaching with medications like GLP-1s to forge health habits and drive long-term health outcomes. In this episode, we discuss using medication as a catalyst for behavior change. We also cover:   Shifting revenue from medicated plans Microdosing GLP-1s Building the "Duolingo of Health"   Subscribe to the podcast → insider.fitt.co/podcast  Subscribe to our newsletter → insider.fitt.co/subscribe  Follow us on LinkedIn → linkedin.com/company/fittinsider  Website: www.noom.com  Programs for weight loss and proactive health available   -   The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities. Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/  Chapters: (00:00) Introduction (01:30) What's changed at Noom (02:00) Revenue shift (03:25) GLP-1s as catalyst  (04:20) Food noise silence (05:35) Discontinuation rates (06:35) Medication to maintenance (07:00) Microdosing GLP-1s (08:35) Challenges and strategies (09:50) Self-experimentation & preventative health (12:20) Other supplements (14:05) Stacking habits (15:35) What belongs in clinical care? (16:20) Litmus test (17:20) Research investment and peer-reviewed studies (18:25) Largest microdose dataset in the world (19:30) Virtuous loop (20:30) Cue, micro-habit, reward framework (21:25) Gamification (22:32) Behavior change foundation  (24:00) Condition advantage over competitors (26:00) Women's health, blood testing, & category expansion (26:35) Behavior, diagnostics, and clinical care (28:15) Blood testing for proactive health (29:20) Care stacks and vertical integration trends (31:10) IPO timeline and public market readiness (32:35) 2026 goals (33:40) Conclusion

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the discontinuation of lasmiditan, the new DAAN designation, and the use of alteplase after eye stroke.

Join Phillip Cuculich, MD and his guests Tina Baykaner, MD, MPH and Atul Verma, MD, FHRS for this lively discussion of a cutting edge topic. The ALONE-AF trial evaluated whether patients who remained free of atrial fibrillation for at least one year after catheter ablation could safely discontinue long-term oral anticoagulation. In this randomized study of more than 800 patients, stopping anticoagulation resulted in similarly low rates of stroke or systemic embolism and significantly fewer major bleeding events compared with continuing therapy. The findings suggest that, in carefully selected post-ablation patients, long-term anticoagulation discontinuation may be a safe and beneficial strategy.   Learning Objectives Evaluate the methodology and patient selection criteria of the ALONE-AF randomized trial to understand which post-ablation patients may be appropriate candidates for long-term anticoagulation discontinuation. Interpret the trial's primary and secondary outcomes to assess the comparative risks of thromboembolism and major bleeding in patients who discontinue versus continue oral anticoagulation after successful AF ablation. Discuss the clinical implications of ALONE-AF for shared decision-making, guideline considerations, and the development of individualized anticoagulation strategies following catheter ablation.   Article Authors Daehoon Kim, MD; Jaemin Shim, MD; Eue-Keun Choi, MD, Il-Young Oh, MD; Jun Kim, MD; Young Soo Lee, MD; Junbeom Park, MD; Jum-Suk Ko, MD; Kyoung-Min Park, MD; Jung-Hoon Sung, MD; Hyung Wook Park, MD; Hyung-Seob Park, MD; Jong-Youn Kim, MD, Ki-Woon Kang, MD; Dongmin Kim, MD; Jin-Kyu Park, MD; Dae-Hyeok Kim, MD; Jin-Bae Kim, MD; Hee Tae Yu, MD; Tae-Hoon Kim, MD; Jae-Sun Uhm, MD; Hui-Nam Pak, MD1; Boyoung Joung, MD; for the ALONE-AF Investigators   Podcast Contributors Tina Baykaner, MD, MPH Phillip Cuculich, MD Atul Verma, MD, FHRS   Article for Discussion

In this episode, we discuss how Meta and its algorithms shape what we see online, why the penny has finally been discontinued, and the legal and economic complications that follow from eliminating small denominations. For the “foolishness of the week,” we highlight a small-town newspaper that was awarded a $3 million settlement stemming from an unlawful raid, and the First Amendment implications it raises. We examine the disconnect between a sluggish economy and soaring asset prices, discuss how Fed policy and excess liquidity fuel inflation in financial markets, and consider what rising bubbles in stocks, housing, gold, and bitcoin mean for retirement planning and long-term investment behavior. 00:00 Introduction and Overview 00:37 Meta Entertainment and Hot Wheels 04:49 The Discontinuation of the Penny 06:45 How Eliminating Pennies Would Affect Retailers and Consumers 11:18 Who Actually Has the Power to Change U.S. Currency 12:49 Reflections on U.S. Currency 15:57 Foolishness of the Week: $3 Million Newspaper Raid Settlement 18:05 Press Freedom, Accountability, and Government Overreach 20:58 Understanding Financial Bubbles 24:29 Why the Markets Aren't Reflecting Economic Reality 27:35 The Fed's Liquidity Regime and Phantom Wealth 33:56 Unintended Consequences of Economic Policies 37:55 Investing in a Changing Economy 38:49 Retirement Planning in a Bubble-Driven Economy 41:11 Learning from Historical Economic Events 43:14 Personal Anecdotes and Economic Trends 45:12 Future of Investments Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, we discuss how Meta and its algorithms shape what we see online, why the penny has finally been discontinued, and the legal and economic complications that follow from eliminating small denominations. For the “foolishness of the week,” we highlight a small-town newspaper that was awarded a $3 million settlement stemming from an unlawful raid, and the First Amendment implications it raises. We examine the disconnect between a sluggish economy and soaring asset prices, discuss how Fed policy and excess liquidity fuel inflation in financial markets, and consider what rising bubbles in stocks, housing, gold, and bitcoin mean for retirement planning and long-term investment behavior. 00:00 Introduction and Overview 00:37 Meta Entertainment and Hot Wheels 04:49 The Discontinuation of the Penny 06:45 How Eliminating Pennies Would Affect Retailers and Consumers 11:18 Who Actually Has the Power to Change U.S. Currency 12:49 Reflections on U.S. Currency 15:57 Foolishness of the Week: $3 Million Newspaper Raid Settlement 18:05 Press Freedom, Accountability, and Government Overreach 20:58 Understanding Financial Bubbles 24:29 Why the Markets Aren't Reflecting Economic Reality 27:35 The Fed's Liquidity Regime and Phantom Wealth 33:56 Unintended Consequences of Economic Policies 37:55 Investing in a Changing Economy 38:49 Retirement Planning in a Bubble-Driven Economy 41:11 Learning from Historical Economic Events 43:14 Personal Anecdotes and Economic Trends 45:12 Future of Investments Learn more about your ad choices. Visit podcastchoices.com/adchoices

With Maura Marcucci, Clinical Institute Humanitas IRCCS, Rozzano - Italy and McMaster University, Hamilton - Canada and Mauro Chiarito, Clinical Institute Humanitas IRCCS, Rozzano - Italy and Icahn School of Medicine at Mount Sinai, NYC - USA. Link to European Heart Journal paper Link to European Heart Journal editorial

Send us a textKeywordscar news, discontinued cars, luxury cars, muscle cars, automotive trends, 2025 car models, car culture, car reviews, automotive industry, car enthusiastsSummaryIn this episode of the Two Car Guys podcast, hosts John and Adam discuss the upcoming discontinuation of various car models in 2025, including iconic sports cars, luxury vehicles, and mainstream cars. They delve into the implications of these changes on the automotive industry and car culture, while also touching on the future of muscle cars and upcoming automotive events.Takeaways30 cars are getting discontinued in 2025.The last of the GTRs as we know it is gone.The Porsche Cayman and Boxster are leaving the market.The Maserati MC20 is also on the chopping block.Audi is discontinuing several models, including the A4 and A5.The Chevy Malibu is coming to an end, along with the Ford Focus.Alfa Romeo is going all EV, which raises concerns.Muscle cars have seen a decline in popularity.The Viper is rumored to be making a comeback.Upcoming automotive events include F1 races and Petit Le Mans.TitlesThe End of an Era: Cars Discontinued in 2025Luxury Cars Facing the Axe: What's Next?Sound bites"Let's dive right in""The Maserati MC20 is leaving""Alfa Romeo is going all EV"Chapters00:00 Discontinuation of Iconic Cars in 202504:42 Luxury Cars Facing the Axe09:29 Mainstream Cars and Market Trends14:02 The Future of Performance Cars14:23 Reviving the Viper: Hopes and Rumors19:01 The Evolution of Muscle Cars24:19 The Viper Truck: A Unique Beast25:56 Upcoming Events and Exciting CollaborationsSupport the show

TARGET-FIRST: Early Aspirin Discontinuation After PCI in Acute MI Patients

Vilazodone (brand name Viibryd) is an antidepressant with a unique pharmacologic profile compared to most other agents in the SSRI class. While not a first-line choice for every patient, understanding its mechanism, adverse effects, and interaction profile is essential for optimizing therapy and preventing downstream prescribing problems. Mechanism of ActionVilazodone is classified as a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at the 5-HT1A receptor. The SSRI activity increases synaptic serotonin by blocking the serotonin transporter, while partial agonism at 5-HT1A receptors may contribute to antidepressant effects and potentially reduce certain SSRI-associated adverse effects (though clinical evidence for this benefit is mixed). Adverse Effects GI effects – diarrhea, nausea, and vomiting are frequent early in therapy. Taking the medication with food can help minimize these. Insomnia – often dose-related; morning dosing may help. Sexual dysfunction – may be slightly lower than with some SSRIs but still present. Serotonin syndrome – rare but serious, particularly if combined with other serotonergic drugs. Discontinuation syndrome – abrupt cessation can lead to dizziness, irritability, and flu-like symptoms. Drug InteractionsVilazodone is primarily metabolized by CYP3A4. This means: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can increase vilazodone concentrations, potentially worsening side effects—dose reductions may be required. CYP3A4 inducers (e.g., carbamazepine, rifampin, St. John's Wort) can lower drug levels, reducing effectiveness. Other serotonergic agents (e.g., triptans, SNRIs, MAOIs, tramadol, linezolid) increase the risk of serotonin syndrome. Antiplatelets and anticoagulants – SSRIs can impair platelet aggregation, increasing bleeding risk when combined with aspirin, NSAIDs, or warfarin. Prescribing Cascade ExamplesVilazodone's adverse effects can easily lead to unnecessary prescriptions if side effects aren't recognized: GI upset → Acid suppression therapy – Diarrhea or nausea prompts the addition of proton pump inhibitors or antiemetics, instead of adjusting vilazodone dose or timing. Insomnia → Hypnotic initiation – Trouble sleeping results in adding zolpidem or trazodone, without reassessing morning dosing or vilazodone's role. Sexual dysfunction → PDE5 inhibitor prescription – Erectile dysfunction leads to sildenafil use, when the root cause is vilazodone's serotonergic activity. Vilazodone's combination of SSRI and 5-HT1A partial agonist activity makes it somewhat distinct, but its side effect profile and interactions require the same careful monitoring as other antidepressants. Healthcare professionals can play a key role in catching early signs of adverse effects, preventing prescribing cascades, and ensuring drug–drug interactions are managed appropriately.

In this episode, Dr. Daina Parent, ND, sits down with Laurence Katsaras—Naturopath, Acupuncturist, and classically trained Western Herbalist—for a deep dive into incretin hormones, especially GLP-1's and their far-reaching effects on the body. They discuss the interconnected web of health in which all physiological pathways work together, and how GLP-1 medications can distort this web leading to unintended effects elsewhere. They highlight clinical takeaways for keeping the web strong through hormone balance, gut health, herbs, diet, and lifestyle. They explore the pros and cons of GLP-1 receptor agonist medications, herbal and lifestyle recommendations to help manage side effects, and natural approaches that support the body's own ability to regulate these pathways. Laurence also shares insights from his 20 years in the natural medicine industry as a clinician, researcher, and educator. A sought-after speaker in the naturopathic and complementary medicine field across Australia and New Zealand, he is known for translating emerging research into practical, actionable strategies for clinical practice. Don't forget to follow and like our podcast channel to stay up-to-date on upcoming podcast episodes. Highlights of the episode include: GLP-1 medication effects vs. the body's natural GLP-1 hormone activity Risks for women in perimenopause, menopause, and postmenopause: muscle loss and bone health impacts Herbal compounds that stimulate GLP-1 receptors naturally The complex web of health: restoring balance in interconnected physiological systems Broad benefits of bitter herbs on the gut microbiome as part of a holistic approach to metabolic health Podcast Summary 1:30 Defining incretin hormones, including GLP-1 (glucagon-like peptide-1) 5:06 Organs that are influenced by incretin hormones, and how are they affected 7:48 GLP-1 medication effects vs. the body's natural GLP-1 hormone activity 8:53 Side effects of GLP-1 receptor agonist medications 11:00 Concerns about weight loss, muscle loss and rebound weight gain after discontinuing medication 15:30 Importance of continuing holistic diet and lifestyle habits after going off medications 18:20 Risks for women in perimenopause, menopause, and postmenopause: muscle loss and bone health impacts 20:07 Herbal compounds that stimulate GLP-1 receptors naturally—gentle, holistic alternatives without dramatic or rapid changes 29:00 How bitter herbs and foods stimulate incretin hormone production naturally 30:30 Herbs with metabolic benefits and that support GLP-1 function 32:25 Is long-term GLP-1 medication use sustainable considering side effects and costs? Harnessing the body's innate ability to rebalance 33:30 The complex web of health: restoring balance in interconnected physiological systems 36:22 Discontinuation rates of GLP-1 medications: potential for combining herbal approaches with medication 39:00 Herbal safety: choosing the right herb for the right person, only when truly needed 41:14 Broad benefits of bitter herbs on the gut microbiome as part of a holistic approach to metabolic health 47:10 The “interconnected web of health”—how a single strand impacts the whole system 49:20 Clinical guidance for supporting patients considering or currently taking GLP-1 medications

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Eli Lilly has invested $1.3 billion in a partnership with Superluminal, an AI/ML startup focusing on endocrine and cardiometabolic diseases to develop new small molecule obesity medications. Schrodinger has discontinued the development of an early-stage blood cancer drug after two patient deaths. Trump has delayed pharma tariffs citing other priorities. RFK Jr. has been criticized for canceling Barda contracts related to mRNA vaccine research, leading to more vaccine misinformation. Genscript announces a new era of innovation and trust. Other news includes Vedanta downsizing, Abata shutting down.

welcome to wall-e's tech briefing for friday, august 8th! dive into today's top tech stories: openai unveils gpt-5: launched on thursday, this state-of-the-art model enhances chatgpt with faster responses and advanced reasoning, marking a "significant step" towards artificial general intelligence as per ceo sam altman. tesla abandons dojo project: a strategic shift with the discontinuation of its supercomputer effort, reallocating resources and focusing on partnerships with nvidia and samsung instead. ai startup struggle: windsurf, plagued by high costs and competition, sells to google, underscoring the financial pressures in the ai coding sector. xai leadership change: robert keele steps down as head of legal; lily lim takes over, amid ongoing shifts at xai led by elon musk. ads in ai responses: elon musk plans to integrate advertisements into grok's ai responses on x, a move intended to enhance targeted ad revenue post-linda yaccarino's departure. stay tuned for tomorrow's tech updates!

Interview with Sameer Jauhar, PhD, author of Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. Hosted by John Torous, MD. Related Content: Incidence and Nature of Antidepressant Discontinuation Symptoms

Interview with Sameer Jauhar, PhD, author of Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. Hosted by John Torous, MD. Related Content: Incidence and Nature of Antidepressant Discontinuation Symptoms

Interview with Sameer Jauhar, PhD, author of Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. Hosted by John Torous, MD. Related Content: Incidence and Nature of Antidepressant Discontinuation Symptoms

Jaffa fans are coming to grips with the news the orange-coated chocolate treat will soon be no more. Confectionery company RJs has this week confirmed it stopped making the long-time Kiwi favourite earlier this year, and they'll soon vanish from shop shelves. Reporter Jimmy Ellingham visited the home of the Jaffa, the RJs outlet store and factory in Levin, to ask sweet-toothed visitors stocking up on packets of the sweeties how they feel about the end of the Jaffa.

The end of an era for one of our most iconic sweets. Levin confectioner RJ's has discontinued production of Jaffas, due to poor sales. The orange-coated balls of chocolate were previously produced by Cadbury in Dunedin and have been on our shelves for almost a century. Mike Hutcheson, former Managing Director of Saatchi & Saatchi, told Mike Hosking that a competitor would pick up Jaffas in a heartbeat. He says it's not just a sweet, it's a symbol, and it's possible to turn it around and make Jaffas a brand that means something. LISTEN ABOVE See omnystudio.com/listener for privacy information.

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode, we discuss the critical challenges of benzodiazepine discontinuation, exploring Benzodiazepine-Induced Neurological Dysfunction (BIND) and effective support strategies for patients experiencing protracted withdrawal. What can clinicians do when over 50% of patients report finding more help from online forums than from medical professionals? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Strategies for Successful Benzodiazepine Deprescribing Beyond Benzodiazepine Discontinuation: Understanding Life Effects and Support Strategies

Dr. Halley Alexander and Dr. Samuel W. Terman discuss patients' perceived seizure risk, seizure risk tolerance, and risk counseling techniques.  Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200475 

Dr. Halley Alexander talks with Dr. Samuel W. Terman about patients' perceived seizure risk, seizure risk tolerance, and risk counseling techniques.  Read the related article in Neurology® Clinical Practice.  Disclosures can be found at Neurology.org. 

Commentary by Dr. Meixiang Xiang.

In this episode, we explore evidence-based strategies for successful benzodiazepine tapering with addiction psychiatrist Dr. Alexis Ritvo. How can clinicians minimize withdrawal effects while supporting patients through this challenging process? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing Understanding the Principles of Benzodiazepine Tapering

Nucala gains new indication; the FDA are set to require placebo-controlled trials to evaluate COVID-19 vaccines; pruritus reported following discontinuation of antihistamines; oral carbapenem antibiotic looks promising for cUTIs; investigational celiac disease Tx gets Fast Tracked

A News Roundup episode, and an episode of two halves.  We start with a discussion of the recent public Oval Office meeting between Trump and Cyril Ramaphosa, in which Trump harangued the South African president with accusations of 'white genocide' based on 'evidence' which tracks straight back to people in our usual wheelhouse.  Then we move on to a chat about the recent decision by language learning app Duolingo to replace loads of their contributors with AI, plus some dismaying news about Babbel, leading to a discussion of the impending AI jobs crisis.  Then we cap it off with an odd flex for us... a feel good story! Episode Notes: Trump spreads racist South African Farm Murders Memes in meeting with Ramaphosa Trump/Ramaphosa meeting: https://www.youtube.com/watch?v=3TLkZv3gzO0 Response: https://www.cnn.com/2025/05/21/politics/video/trump-ramaphosa-south-africa-video-larry-madowo-vrtc * A check of Trump's false claims about white genocide in South Africa | Reuters https://www.reuters.com/world/us/trump-makes-false-claims-white-genocide-south-africa-during-ramaphosa-meeting-2025-05-21/ Trump's evidence of South Africa ‘white genocide' contains images from DR Congo – The Irish Times https://www.irishtimes.com/world/africa/2025/05/23/trumps-evidence-of-south-africa-white-genocide-contains-images-from-dr-congo/ Trump confronted South African president with ‘evidence' of genocide – here's what the video really showed | The Independent https://www.independent.co.uk/news/world/americas/us-politics/trump-south-africa-genocide-video-b2755625.html Trump ambushes South African president with video and false claims of anti-white racism | Trump administration | The Guardian https://www.theguardian.com/us-news/2025/may/21/trump-south-africa-president-meeting?utm_source=dlvr.it&utm_medium=bluesky&CMP=bsky_gu What's Behind Trump's South Africa Obsession? | Benjamin Fogel | TMR https://youtu.be/gR_gwPI5l-0?si=QfWeEuoosYeUD-JG South Africa to offer Elon Musk Starlink deal ahead of Trump meeting | Business Insider Africa https://africa.businessinsider.com/local/markets/south-africa-to-offer-elon-musk-starlink-deal-ahead-of-trump-meeting/v0k8bxk?op=1 White Nationalists Praise Trump's Promotion Of White Genocide Conspiracy Theory – Angry White Men https://angrywhitemen.org/2025/05/22/white-nationalists-praise-trumps-promotion-of-white-genocide-conspiracy-theory/ Exclusive: Trump Shared Racist, Flat-Earth Facebook Account With South African President https://www.meidasplus.com/p/exclusive-trump-shared-racist-flat Roaming Charges: White Lies About White Genocide - CounterPunch.org https://www.counterpunch.org/2025/05/23/white-lies-about-white-genocide/ DR Congo: Killings, Rapes by Rwanda-Backed M23 Rebels | Human Rights Watch https://www.hrw.org/news/2023/06/13/dr-congo-killings-rapes-rwanda-backed-m23-rebels As Goma ceasefire largely holds, Congo rushes to bury bodies from rebel offensive | Reuters https://www.reuters.com/world/africa/east-congo-city-goma-rushes-bury-bodies-after-rebel-offensive-2025-02-04/ A white nationalist moved to Idaho in search of an ‘ethnic enclave.' He's not alone. https://www.spokesman.com/stories/2022/jul/21/a-white-nationalist-moved-to-idaho-in-search-of-an/ * Duolingo Replacing Contract Workers With AI The Verge, “Duolingo will replace contract workers with AI” https://www.theverge.com/news/657594/duolingo-ai-first-replace-contract-workers “AI isn't just a productivity boost,” von Ahn says. “It helps us get closer to our mission. To teach well, we need to create a massive amount of content, and doing that manually doesn't scale. One of the best decisions we made recently was replacing a slow, manual content creation process with one powered by AI. Without AI, it would take us decades to scale our content to more learners. We owe it to our learners to get them this content ASAP.” von Ahn's email follows a similar memo Shopify CEO Tobi Lütke sent to employees and recently shared online. In that memo, Lütke said that before teams asked for more headcount or resources, they needed to show “why they cannot get what they want done using AI.” Fortune, “Duolingo CEO walks back AI-first comments: ‘I do not see AI as replacing what our employees do'” “To be clear: I do not see AI as replacing what our employees do (we are in fact continuing to hire at the same speed as before),” he wrote. “I see it as a tool to accelerate what we do, at the same or better level of quality. And the sooner we learn how to use it, and use it responsibly, the better off we will be in the long run.” Babbel quietly ending Babbel Live Babbel Support, “Discontinuation of Babbel Live” https://support.babbel.com/hc/en-us/articles/26749152437522-Discontinuation-of-Babbel-Live “Babbel Live was introduced in 2021. Knowing the power of human teachers, we aimed to offer our learners this experience from their homes. Over time, however, we did see a clear trend: the majority of them did not accept Babbel Live as part of their language learning path, making it impossible for us to sustain it as a business. This change will help us achieve our goal of helping you become fluent in your new language quickly by enabling us to focus on improving our app, which most learners, especially beginners, prefer.” Boycott Over Upcoming E-sports Event in Riyadh Makes Geoguessr Change Its Stance Geoguessr Community Protests Esports World Cup by Disabling Popular Maps. https://www.si.com/esports/news/geoguessr-protests-esports-world-cup Statement from Feneb, one of the World Championship players, about his decision to boycott the Riyadh event. https://discord.com/channels/1003591679644807229/1026965093331779634/1375003211513204746 “The decision to participate in the Esports World Cup, which is directly funded by the Saudi Arabian government in an effort to distract public attention from the above human rights violations, is thus directly incompatible with any stated aims by GeoGuessr to promote an inclusive and diverse community, and extremely disappointing. I also do not want to dismiss the issue of hosting a tournament in Saudi Arabia, regardless of whether the event is directly run by the Saudi government or not. It is completely unnecessary to host a tournament in a country which some current or possible future world league players would be unable to travel to safely.” Statement from Geoguessr regarding their decision to reverse the event in Riyadh (Reddit) https://www.reddit.com/r/geoguessr/comments/1ksky0k/geoguessr_is_withdrawing_from_the_esports_world/ Geoguessr challenge links: (Standard) World Map https://www.geoguessr.com/challenge/MIJFcVhIFNpVapVs https://www.geoguessr.com/challenge/sedHxYRoMPdmFxdZ https://www.geoguessr.com/challenge/eIRYCYBhuUUBVIT2 An Official World https://www.geoguessr.com/challenge/tK9A8O1KUXQfZgCu https://www.geoguessr.com/challenge/NGYJ4uk0WhxNR5Ui https://www.geoguessr.com/challenge/Yc4uD6P8lFISKIgb A Community World https://www.geoguessr.com/challenge/B87Y20LMvmtDvUwN https://www.geoguessr.com/challenge/I9ub9gc9CmoEQpjn https://www.geoguessr.com/challenge/ZwKxnW3Ms9UTZZt6 * The AI jobs crisis is here, now - by Brian Merchant https://www.bloodinthemachine.com/p/the-ai-jobs-crisis-is-here-now Something Alarming Is Happening to the Job Market - The Atlantic https://www.theatlantic.com/economy/archive/2025/04/job-market-youth/682641/  Show Notes: Please consider donating to help us make the show and stay ad-free and independent.  Patrons get exclusive access to at least one full extra episode a month plus all backer-only back-episodes. Daniel's Patreon: https://www.patreon.com/danielharper/posts Jack's Patreon: https://www.patreon.com/user?u=4196618&fan_landing=true IDSG Twitter: https://twitter.com/idsgpod Daniel's Twitter: @danieleharper Jack's (Locked) Twitter: @_Jack_Graham_ Jack's Bluesky: @timescarcass.bsky.social Daniel's Bluesky: @danielharper.bsky.social IDSG on Apple Podcasts: https://podcasts.apple.com/us/podcast/i-dont-speak-german/id1449848509?ls=1

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 67 Which Antidepressants Have the Highest Risk of Discontinuation Symptoms?

In this episode, the Surgical Endoscopy team, accompanied by Chief Medical Officer Dr. Brian Dunkin of Boston Scientific, review primary and revisional endoscopic treatment options for bariatric patients. They focus on the emerging data available for procedures such as endoscopic sleeve gastroplasty (ESG) and endoscopic gastrojejunal revision (EGJR) and offer technical tips on how to perform the procedures. In addition, they discuss accessibility challenges for patients and provide insight into the future direction of bariatric endoscopy as a field.  Hosts: ·      Dr. Sullivan “Sully” Ayuso, Minimally Invasive Surgery, Endeavor Health (Evanston, IL), @SAyusoMD (Twitter) ·      Dr. Trevor Crafts, Minimally Invasive Surgeon, Rocky Mountain VA Medical Center (Denver, CO), @CraftsTrevor (Twitter)  ·      Dr. H. Masson Hedberg, Minimally Invasive Surgeon, Endeavor Health (Evanston, IL) ·      Dr. Michael Ujiki, Professor and Louis Biegler Chair of Surgery, Endeavor Health (Evanston, IL), @UjikiMike ·      Dr. Brian Dunkin, Chief Medical Officer at Boston Scientific, @briandunkinmd Learning Objectives:  -       Identify and Describe Common Endobariatric Procedures: Learners will be able to name and briefly describe at least three common endobariatric procedures discussed in the episode, including Endoscopic Sleeve Gastroplasty (ESG), Endoscopic GJ Revisions (Transoral Outlet Reduction - TORR/EGJR), and Intragastric Balloons, along with their historical context and evolution. -       Explain the Mechanism and Benefits of Endoscopic Sleeve Gastroplasty (ESG): Learners will be able to articulate the procedural technique of ESG, including the U-shaped suture pattern, its impact on gastric volume reduction, and the proposed mechanisms of weight loss, such as slowed gastric emptying and hormonal changes, as compared to laparoscopic sleeve gastrectomy. -       Discuss the Role of Technology and Training in Endobariatrics: Learners will be able to explain the significance of endoscopic suturing devices like the Overstitch in the advancement of endobariatric procedures and recognize the importance of specialized training, including the recommendations against fundal suturing for safety during the initial learning curve. -       Compare and Contrast Endobariatric Procedures with Surgical and Pharmacological Obesity Treatments: Learners will be able to discuss the position of endobariatric procedures as a "gap therapy" in the spectrum of obesity treatments, highlighting their benefits such as reduced invasiveness, lower complication rates, faster recovery, and increased patient access compared to surgery, as well as their potential role in conjunction with pharmacologic therapies like GLP-1 agonists. -       Recognize Key Considerations and Potential Complications of Endobariatric Procedures: Learners will be able to identify important technical considerations during ESG, such as achieving full-thickness bites while avoiding injury to adjacent organs, and describe common post-procedure issues associated with intragastric balloons, including nausea, vomiting, and the need for general anesthesia during removal. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity: https://pubmed.ncbi.nlm.nih.gov/39888616/ Surgical Endoscopy Series Ep. 1: An Introduction to Surgical Endoscopy: https://app.behindtheknife.org/podcast/surgical-endoscopy-series-ep-1-an-introduction-to-surgical-endoscopy Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

SUMMARYIn this episode of "Right About Now," host Ryan Alford and co-host Chris Hansen discuss key business news, including Donald Trump's address to Congress, the discontinuation of Skype, and the impact of tariffs on the U.S. economy. They reflect on the decline of Skype in favor of platforms like Zoom and WhatsApp, and explore the evolving job market influenced by AI. The conversation also touches on the importance of diversity in hiring, the benefits of entrepreneurship, and the volatile nature of cryptocurrency markets. The episode emphasizes staying informed and adaptable in a rapidly changing economic landscape.TAKEAWAYSBusiness news highlights and current events overviewKey takeaways from Donald Trump's address to CongressImplications of tariffs on the U.S. economyDiscontinuation of Skype and its impact on communicationPolitical climate and its influence on business decisionsEconomic insights, including discussions on tax cutsDiversity in hiring practices and merit-based hiringThe role of technology and AI in the job marketThe importance of entrepreneurship and brand building on social mediaThe evolving landscape of communication platforms and their alternatives If you enjoyed this episode and want to learn more, join Ryan's newsletter https://ryanalford.com/newsletter/ to get Ferrari level advice daily for FREE. Learn how to build a 7 figure business from your personal brand by signing up for a FREE introduction to personal branding https://ryanalford.com/personalbranding. Learn more by visiting our website at www.ryanisright.comSubscribe to our YouTube channel www.youtube.com/@RightAboutNowwithRyanAlford.

In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Antipsychotic Withdrawal Syndrome: Symptoms, Risks, and Prevention Strategies

“Behind the Evidence” is the addiction medicine podcast of the Grayken Center for Addiction at Boston Medical Center, and a project of the Center's free bimonthly newsletter Alcohol, Other Drugs, and Health: Current Evidence (AODH). This episode was recorded in June 2024 and features an interview with Joao P. De Aquino, MD on his article published in the American Journal of Drug and Alcohol Abuse: “The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.” And an interview with Donovan Maust, MD on his article in JAMA Network Open: “Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy.” Click the following links to read AODH's summaries of Dr De Aquino and Dr. Maust's articles.Also discussed: Christine PJ, Lodi S, Hsu HE, et al. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024;119(7):1313-1321.Hosts: Honora L. Englander, MD and Marc R. Larochelle, MDProduction: Raquel Silveira, MBAEditing: Casy Calver, PhDMusic and cover art: Mary Tomanovich, MAMiriam Komaromy, MD is the Medical Director of the Grayken Center for Addiction, and co-Editor-in-Chief of AODH, together with David Fiellin, MD.Learn more about AODH and subscribe for free at www.aodhealth.org“Behind the Evidence” is supported by the Grayken Center for Addiction at Boston Medical Center. It is intended for educational purposes only, and should not be considered medical advice. The views expressed here are our own, and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

Medboard EU EU MDR and IVDR article 10a - Discontinuation of Supply: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02017R0745-20250110#art_10a EU IVDR transition periods - Visual: https://health.ec.europa.eu/document/download/ff7fa114-c539-46b3-9066-4bfbb306e9de_en?filename=timeline_ivdr_en.pdfEUDAMED EMDN: UPDATE or not to UPDATE - MDCG 2024-2 Rev 1 and 2021-12 Rev 1 : https://health.ec.europa.eu/document/download/ff8d6bf6-785f-48e1-beaf-2cfe13f59fd7_en?filename=mdcg_2025-2_en.pdf MDCG 2024-2: https://health.ec.europa.eu/document/download/de470384-e8be-45e7-a334-226757f8816d_en?filename=mdcg_2024-2_en.pdf MDCG 2021-12: https://health.ec.europa.eu/document/download/d90b3f63-1d62-43e6-bf5f-fb32ea7c47a2_en?filename=md_2021-12_en.pdf Contact points of National Authorities - Bookmark them in case: https://health.ec.europa.eu/document/download/c28e965a-3b7c-4a5b-a6ee-d1724d06f20d_en?filename=md_contact_points_of_national_authorities.pdf EU Battery 2023/1542 - Guidance issued by EU commission: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:C_202500214 Swiss Maintenance of Medical Devices - Guidance for Hospitals: https://www.swissmedic.ch/swissmedic/en/home/medical-devices/reprocessing---maintenance/maintenance.html UK timeline for UKCA - Be ready for 2030: https://assets.publishing.service.gov.uk/media/6718b88738149ce9d09e3894/Infographic_-_Devices_transition_timeline.pdf UK Post-Market Surveillance - Implementation and Template of PSUR: https://www.gov.uk/government/publications/medical-devices-post-market-surveillance-requirements/the-medical-devices-post-market-surveillance-requirements-amendment-great-britain-regulations-2024-guidance-on-implementation https://assets.publishing.service.gov.uk/media/67813b39363ac763c8ede498/Medical_devices_periodic_safety_update_report__PSUR__formatting__1_.pdf PMS Guidance: https://www.gov.uk/government/publications/medical-devices-periodic-safety-update-report-psur/the-medical-devices-post-market-surveillance-requirements-amendment-great-britain-regulations-2024-guidance-on-periodic-safety-update-reports PMS Requirements: https://www.gov.uk/government/publications/medical-devices-post-market-surveillance-requirements/post-market-surveillance-requirements-for-medical-devices-summary-of-main-changes PMS Obligations per device type: https://www.gov.uk/government/publications/medical-devices-post-market-surveillance-requirements/post-market-surveillance-pms-obligations-by-medical-device-type   TUK Vigilance Reporting - Field Safety notices and Example of incidents: https://www.gov.uk/government/publications/medical-devices-examples-of-reportable-incidents FSN: https://www.gov.uk/guidance/effective-field-safety-notices-fsns-guidance-for-manufacturers-of-medical-devices#full-publication-update-history Devices for cardiac ablation: https://www.gov.uk/government/publications/reporting-adverse-incidents-devices-for-cardiac-ablation Joint Replacement implant: https://www.gov.uk/government/publications/reporting-adverse-incidents-joint-replacement-implants#full-publication-update-history Intraocular lenses: https://www.gov.uk/government/publications/reporting-adverse-incidents-intraocular-lenses Insulin pumps and meter systems: https://www.gov.uk/government/publications/reporting-adverse-incidents-insulin-pumps-and-meter-systems   UK guide for IVD - Learn before to re-learn: https://assets.publishing.service.gov.uk/media/67863a313ef063b15dca0f47/Guidance_on_the_regulation_of_IVD_medical_devices_in_GB.pdf Training EU MDR training - Green Belt Certification Program: https://school.easymedicaldevice.com/course/gb33/ Rest of the World: Laboaratory Developed Tests FAQ - Learn all about LDTs: https://www.fda.gov/medical-devices/laboratory-developed-tests-faqs/definitions-and-general-oversight-laboratory-developed-tests-faqs and https://www.fda.gov/medical-devices/laboratory-developed-tests-faqs/medical-device-reporting-complaints-and-corrections-removals-reporting-laboratory-developed-tests How to apply your dossier in Australia - Full guidance by TGA: https://www.tga.gov.au/how-we-regulate/manufacturing/manufacture-medical-device/obtain-and-maintain-regulatory-evidence/australian-regulatory-evidence-options-medical-device-application/tga-conformity-assessment-certification/application-instructions-conformity-assessment Malaysia guidance for HIV Self-test - Placement on the Malaysia Market: https://www.mda.gov.my/index.php/documents/ukk/3480-final-gd-placement-of-hiv-self-test-kit-in-malaysia-market-2nd-edition-pdf/file Import Medical Device for Personnal Use in Malaysia - What means Personal use? https://portal.mda.gov.my/index.php/documents/ukk/3468-draft-public-comment-gd-importation-of-medical-device-for-personal-use-second-edition-updated-2025-pdf/file Alert by Philippines for Product registration - Engaging consultants is not encouraged: https://www.fda.gov.ph/wp-content/uploads/2025/01/FDA-Advisory-No.2025-0033-.pdf Saudi Arabia clearance of Medical Devices - For trainings or conferences: https://www.sfda.gov.sa/sites/default/files/2025-01/Guide%20to%20Conditions%20and%20requirements%20for%20Clearing%20food%2C%20Medical%20devices%2C%20and%20cosmetics%20for%20exhibitions%2C_1.pdf China Medical Device Regulations Round-up 2024 - Cisema.com video: 2024 Round-Up of China Medical Device regulations India update classification lists - List available: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTIzNDI= Podcast Episode 318 - How to register a Medical Device in South Africa - Khanysile Nkuku : https://podcast.easymedicaldevice.com/318-2/ Episode 319 - How to perform your PMS for a Drug-Device Combination - Joan D'Souza: https://podcast.easymedicaldevice.com/319-2/ Episode 320 - Top 5 common NCs on an ISO 13485 audit: https://podcast.easymedicaldevice.com/320-2/ Episode 321 - 6 Tips to grow as a QA RA Manager: https://podcast.easymedicaldevice.com/321-2/

A Rebelião Saudável nasceu da união de diversos profissionais de saúde que pensam diferente e cujo foco é promover saúde e bem estar, com comida de verdade e sem medicamentos. Semanalmente a Rebelião se reune no app Telegram para discussão de tópicos importantes relacionados a Nutrição Humana e Qualidade de vida. Nessa semana, conversamos sobre Agonistas de GLP-1. Referências citadas na transmissão: Itoh Y, Tani M, Takahashi R, Yamamoto K. Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide. Diabetol Int. 2024 Sep 9;15(4):850-854. doi: 10.1007/s13340-024-00751-4. PMID: 39469548; PMCID: PMC11512937. Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, Rajpathak S, Iglay K. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Patient Prefer Adherence. 2020 Nov 27;14:2337-2345. doi: 10.2147/PPA.S277676. PMID: 33273810; PMCID: PMC7708309. Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Garvey WT. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023 Mar;31(3):703-715. doi: 10.1002/oby.23673. Epub 2023 Jan 18. PMID: 36655300. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185. Hengist A, Sciarrillo CM, Guo J, Walter M, Hall KD. Gut-derived appetite hormones do not explain energy intake differences in humans following low-carbohydrate versus low-fat diets. Obesity (Silver Spring). 2024 Sep;32(9):1689-1698. doi: 10.1002/oby.24104. Epub 2024 Aug 7. PMID: 39113385; PMCID: PMC11357890. B Liao, C Able, J Sonstein, T Kohn, (157) Prescribing Ozempic and Wegovy for Weight Loss is Associated with an Increased Risk of Erectile Dysfunction and Hypogonadism in Non-Diabetic Males, The Journal of Sexual Medicine, Volume 21, Issue Supplement_1, February 2024, qdae001.148, https://doi.org/10.1093/jsxmed/qdae001.148 Ajude a rebelião saudável! Seja um apoiador do nosso movimento e garanta que as informações transmitidas continuarão gratuitas para todos! Além de ajudar, você terá acesso a um post mensal exclusivo para apoiadores! Acesse https://apoia.se/rebeliaosaudavel e contribua com a quantia que puder! Ajude a manter esse conteúdo vivo! #facapartedarebeliao Você também pode participar da discussão e da Rebelião. Toda quarta feira, às 7:00, estaremos ao vivo no Telegram, basta acessar o nosso canal: https://t.me/RebeliaoSaudavel. Se você gosta de nosso trabalho, deixe um review 5 estrelas e faça um comentário no seu app de podcast. Essa atitude é muito importante para a Rebelião saudável e vai ajudar nosso movimento a chegar a cada vez mais pessoas. Você também pode nos acompanhar no instagram, http://www.instagram.com/henriqueautran. E em nosso canal do YouTube: https://youtube.com/c/henriqueautran.

A new year and a new beginning. Special guest co-host Pedro Mendes joins Dr. Chris Labos to answer a viewer question about menopause. Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE Email us your questions at thebodyofevidence@gmail.com. Assistant researcher: Aigul Zaripova, MD Editor: Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause- cancer Obviously, I'm not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: Geographic variability of menopausal symptoms 1) Nappi RE et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021 May 24;28(8):875-882. doi: 10.1097/GME.0000000000001793. 2) Nappi RE, et al. Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey. Maturitas. 2023 Jan;167:66-74. doi: 10.1016/j.maturitas.2022.09.006. What's the normal duration of symptoms 3) Avis NE, et al. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001/jamainternmed.2014.8063. The Women's Health Initiative (WHI) studies Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321. Anderson GL et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701-12. doi: 10.1001/jama.291.14.1701. Decline in HRT after WHI studies Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012 Sep;120(3):595-603. doi: 10.1097/AOG.0b013e318265df42. Danish Osteoporosis Prevention Study Schierbeck LL metal. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012 Oct 9;345:e6409. doi: 10.1136/bmj.e6409. Kronos Early Estrogen Prevention Study (KEEPS) Harman SM, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014 Aug 19;161(4):249-60. doi: 10.7326/M14-0353. Kronos Early Estrogen Prevention Study (KEEPS) Hodis HN et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016 Mar 31;374(13):1221-31. doi: 10.1056/NEJMoa1505241. Stopping hormonal therapy Berman RS et al. Risk factors associated with women's compliance with estrogen replacement therapy. J Womens Health. 1997 Apr;6(2):219-26. doi: 10.1089/jwh.1997.6.219. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med. 2005 Dec 19;118 Suppl 12B:163-5. doi: 10.1016/j.amjmed.2005.09.051. Tapering vs. abrupt stop or hormonal therapy Haimov-Kochman R et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause. 2006 May-Jun;13(3):370-6. doi: 10.1097/01.gme.0000186663.36211.c0. PMID: 16735933.

Welcome back Rounds Table Listeners!We are back today with a solo episode with Dr. John Fralick!This week, he will discuss a paper exploring whether Renin-Angiotensin System Inhibitors should be held before major non-cardiac surgery. Here we go!Continuation versus Discontinuation of Renin-Angiotensin System Inhibitors Before Major Non-Cardiac Surgery: The Stop-or-Not Randomized Clinical Trial (0:00 – 6:16).And for the Good Stuff:"Tweetorials" by Tony Breu (6:16 – 7:11).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Introduction: Host: Jr. Journey through the Sega systems, focusing on the Sega Dreamcast. Sega's aim to redefine gaming after the failure of the Sega Saturn. Dreamcast's sleek design, 128-bit processing power, and built-in modem for online play. The Revolutionary Dreamcast: Introduction of online gaming, a concept revolutionary at the time. Remarkable launch lineup, including Sonic Adventure and Soul Calibur. Second Network groundbreaking online capabilities. Formation of virtual communities through multiplayer games. Challenges Faced by Dreamcast: Competition from the PlayStation 2, with superior graphics and extensive game library. Breached security measures leading to rampant piracy. Revenue erosion and alienation of third-party developers. Notable Games and Legacy: Memorable games such as Jet Grind Radio, Skies of Arcadia, and Power Stone. Sega's uphill battle against competitors. Discontinuation of the Dreamcast in 2001, marking Sega's exit from the hardware business. Legacy of Dreamcast's innovation, including features like the visual memory unit and interactive fishing controller. Beloved cult classic status among collectors and gaming enthusiasts. Partnership with Xbox showcasing Sega's potential as a developer. Conclusion: Dreamcast's impact on the gaming landscape and its competitive nature. Appreciation for games like Crazy Taxi, Phantasy Star Online, and Resident Evil Code Veronica. Gratitude for Sega's contribution to the gaming industry and encouragement to seek out uncommon places in gaming.

JAMA Editor in Chief Kirsten Bibbins-Domingo reviews 4 JAMA trials presented at this year's European Society of Cardiology (ESC) Congress on antihypertensive continuation before elective surgery, potassium supplementation after cardiac surgery, pulmonary vein isolation for symptomatic atrial fibrillation, and a triple-drug combination pill for resistant hypertension in Africa. Related Content: Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria Is a Low-Dose Triple-Drug Combination Pill Protocol the Answer for Hypertension Control in Sub-Saharan Africa? Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation

Sky's voice, Copilot+ Surface devices, Car Thing's discontinuation OpenAI didn't copy Scarlett Johansson's voice for ChatGPT, records show China's latest answer to OpenAI is 'Chat Xi PT' Microsoft unveils Copilot+ PCs with generative AI capabilities baked in Pioneering instant messaging program ICQ is finally shutting down after nearly 30 years Google scrambles to manually remove weird AI answers in search Rabbit Holed Elon Musk says AI will take all our jobs A jury hands Bungie a victory in a landmark anti-cheating decision Atari Acquires Intellivision Brand Congress Just Made It Basically Impossible to Track Taylor Swift's Private Jet Spotify is going to break every Car Thing gadget it ever sold Kabosu, Shiba Inu dog who inspired 'Doge' meme, dies at 18 Bitcoin pizza day C. Gordon Bell, Creator of a Personal Computer Prototype, Dies at 89 Host: Leo Laporte Guests: Christina Warren, Wesley Faulkner, and Alex Wilhelm Download or subscribe to this show at https://twit.tv/shows/this-week-in-tech Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: expressvpn.com/twit canary.tools/twit - use code: TWIT NetSuite.com/TWIT bitwarden.com/twit IntouchCX.com/twit